Description

Simple

A chemotherapy agent used for the treatment of certain types of cancer.

Clinical

An antineoplastic kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Overview

Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Pharmacology

Indication

Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated he... Read more

Pharmacodynamic

Mean IC50 of approximately 2.1 μg/mL.

Mechanism of action

ZD-6474 is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (REarranged during Transfection) tyrosine kinases.

VEGFR- and EGFR-dependent signalling are both clinically validated pathways in cancer, including... Read more

Absorption

Slow- peak plasma concentrations reached at a median 6 hours. On multiple dosing, Vandetanib accumulates about 8 fold with steady state reached after around 3 months.

Protein binding

Protein binding of about 90%.

Volume of distribution

Vd of about 7450 L.

Clearance

Information currently not available.

Half life

Median half life of 19 days.

Route of elimination

About 69% was recovered following 21 days after a single dose of vandentanib. 44% was found in feces and 25% in urine.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Congenital prolonged QT syndrome
      • Drugbank Id: DBCOND0108423

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vandetanib
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
3,5-diiodothyropropionic acid
The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Vandetanib.
3,5-Diiodotyrosine
The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Vandetanib.
Abaloparatide
The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Vandetanib.
Abemaciclib
Vandetanib may decrease the excretion rate of Abemaciclib which could result in a higher serum level.
Abexinostat
The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Vandetanib.
Acebutolol
The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Vandetanib.
Aceprometazine
The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Vandetanib.
Acetaminophen
The serum concentration of Acetaminophen can be increased when it is combined with Vandetanib.
Acetyldigoxin
Vandetanib may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.
Acrivastine
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Vandetanib.
Adenosine
The risk or severity of QTc prolongation can be increased when Adenosine is combined with Vandetanib.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Vandetanib.
Agmatine
The serum concentration of Agmatine can be increased when it is combined with Vandetanib.
Ajmaline
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Vandetanib.
Alfuzosin
The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Vandetanib.
Alimemazine
The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Vandetanib.
Allopurinol
Vandetanib may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Alpelisib
The serum concentration of Alpelisib can be increased when it is combined with Vandetanib.
Alvocidib
Vandetanib may decrease the excretion rate of Alvocidib which could result in a higher serum level.
Amantadine
The serum concentration of Vandetanib can be increased when it is combined with Amantadine.
3 References
  1. 1 . Bates D: ZD-6474. AstraZeneca. Curr Opin Investig Drugs. 2003 Dec;4(12):1468-72.PubMed: 14763134
  2. 2 . Ton GN, Banaszynski ME, Kolesar JM: Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm. 2013 May 15;70(10):849-55. doi: 10.2146/ajhp120253.PubMed: 23640345
  3. 3 . Andriamanana I, Gana I, Duretz B, Hulin A: Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:83-91. doi: 10.1016/j.jchromb.2013.01.037. Epub 2013 Mar 16.PubMed: 23562906